Journal Watch · Frontiers in Immunology · 2026
Divergent CD45<sup>+</sup> immune landscapes shape the lung tumor microenvironment.
This atlas identifies genotype-specific immune vulnerabilities with potential relevance for precision immunotherapy in non-small cell lung cancer.
TL;DR
This atlas identifies genotype-specific immune vulnerabilities with potential relevance for precision immunotherapy in non-small cell lung cancer.
Key findings
- Subclustering revealed specialized changes across B cell (resting, mature, pre-Bcr, late pro-B, plasma), T cell (Cd4<sup>+</sup>, Cd8<sup>+</sup>, memory, activated, Treg, Th17), NK cell (Fcgr3<sup>high</sup>, Fcgr3<sup>low</sup>, Xcl1<sup>+</sup>), and macrophage (Ace<sup>+</sup>, Bcr<sup>+</sup>, Ccr2<sup>+</sup>, Cd3<sup>+</sup>, metabolic, MHCII<sup>+</sup>) subsets.
- Ligand-receptor analyses highlighted dense inflammatory networks in LLC1 tumors versus metabolically tuned signaling in Kras<sup>LA2</sup> tumors.<h4>Conclusion</h4>Distinct CD45<sup>+</sup> immune landscapes, characterized by inflammatory suppression in LLC1 and metabolic adaptation in Kras<sup>LA2</sup> tumors, shape lung tumor biology.
- This atlas identifies genotype-specific immune vulnerabilities with potential relevance for precision immunotherapy in non-small cell lung cancer.
What they did
Understanding these roles is essential for developing targeted therapies that harness the beneficial effects of CD45<sup>+</sup> cells while mitigating their harmful effects.<h4>Methods</h4>We performed single-cell RNA sequencing of sorted CD45<sup>+</sup> immune cells from healthy lungs, orthotopic LLC1 tumors, and Kras<sup>LA2</sup> (Kras) genetically engineered tumors. Analyses included immune composition, transcriptional programs, differentiation trajectories, metabolic states, and ligand-receptor-based intercellular communication networks.<h4>Results</h4>Four major immune compartments, B cells, T cells, NK cells, and macrophages, underwent model-specific remodeling. LLC1 tumors showed B cell expansion and T and NK cell reduction, with inflammatory, stress-response, and NF-κB/TNF-dominant programs. Kras<sup>LA2</sup> tumors retained a balanced immune composition but exhibited metabolic rewiring, elevated antigen-presentation signatures, and selective intercellular signaling.
Full abstract (original)
Background: <h4>Background</h4>The lung tumor microenvironment (TME) plays a crucial role in the progression and metastasis of lung cancer. It consists of various cell types that interact in complex ways to influence tumor behavior. CD45<sup>+</sup> cells, as a component of the TME, have complex and multifaceted roles in lung cancer. The balance between the anti-tumor and pro-tumor functions of CD45<sup>+</sup> cells can significantly affect lung cancer outcomes.
What they did: Understanding these roles is essential for developing targeted therapies that harness the beneficial effects of CD45<sup>+</sup> cells while mitigating their harmful effects.<h4>Methods</h4>We performed single-cell RNA sequencing of sorted CD45<sup>+</sup> immune cells from healthy lungs, orthotopic LLC1 tumors, and Kras<sup>LA2</sup> (Kras) genetically engineered tumors. Analyses included immune composition, transcriptional programs, differentiation trajectories, metabolic states, and ligand-receptor-based intercellular communication networks.<h4>Results</h4>Four major immune compartments, B cells, T cells, NK cells, and macrophages, underwent model-specific remodeling. LLC1 tumors showed B cell expansion and T and NK cell reduction, with inflammatory, stress-response, and NF-κB/TNF-dominant programs. Kras<sup>LA2</sup> tumors retained a balanced immune composition but exhibited metabolic rewiring, elevated antigen-presentation signatures, and selective intercellular signaling.
Results & conclusions: Subclustering revealed specialized changes across B cell (resting, mature, pre-Bcr, late pro-B, plasma), T cell (Cd4<sup>+</sup>, Cd8<sup>+</sup>, memory, activated, Treg, Th17), NK cell (Fcgr3<sup>high</sup>, Fcgr3<sup>low</sup>, Xcl1<sup>+</sup>), and macrophage (Ace<sup>+</sup>, Bcr<sup>+</sup>, Ccr2<sup>+</sup>, Cd3<sup>+</sup>, metabolic, MHCII<sup>+</sup>) subsets. Ligand-receptor analyses highlighted dense inflammatory networks in LLC1 tumors versus metabolically tuned signaling in Kras<sup>LA2</sup> tumors.<h4>Conclusion</h4>Distinct CD45<sup>+</sup> immune landscapes, characterized by inflammatory suppression in LLC1 and metabolic adaptation in Kras<sup>LA2</sup> tumors, shape lung tumor biology. This atlas identifies genotype-specific immune vulnerabilities with potential relevance for precision immunotherapy in non-small cell lung cancer.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1765833 · PubMed 41737220.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
This atlas identifies genotype-specific immune vulnerabilities with potential relevance for precision immunotherapy in non-small cell lung cancer.
What type of study is this?
It is a genomics / omics study, published in Frontiers in Immunology in 2026. Understanding these roles is essential for developing targeted therapies that harness the beneficial effects of CD45<sup>+</sup> cells while mitigating their harmful effects.<h4>Methods</h4>We performed single-cell RNA sequencing of sorted CD45<sup>+</sup> immune cells from healthy lungs, orthotopic LLC1 tumors, and Kras<sup>LA2</sup> (Kras) genetically engineered tumors.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1765833. PubMed ID: 41737220. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/divergent-cd45-lt-sup-gt-lt-sup-gt-immune-landscapes-shape-the-lung-tumo-765833/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides